$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
克唑替尼治疗ALK阳性NSCLC患者的疗效优于化疗
2025-10-19 11:44:20
Check Details
色瑞替尼获FDA批准用于ALK阳性肺癌一线治疗
2025-10-19 11:44:20
Check Details
奥希替尼治疗非小细胞肺癌优于吉非替尼
2025-10-19 11:44:20
Check Details
克唑替尼治疗MET外显子14跳跃突变肺腺癌及循环肿瘤细胞监测
2025-10-19 11:44:20
Check Details
奥希替尼一线治疗EGFR突变非小细胞肺癌患者
2025-10-19 11:44:20
Check Details
色瑞替尼肺癌的一线治疗药物
2025-10-19 11:44:20
Check Details
克唑替尼治疗的ALK肺癌时的估计肾小球滤过率降低
2025-10-19 11:44:20
Check Details
在服用易瑞沙之前为何要做EGFR检测?
2025-10-19 11:44:20
Check Details
服用阿法替尼多久产生耐药?
2025-10-19 11:44:20
Check Details
阿来替尼一线治疗ALK阳性肺癌患者数据
2025-10-19 11:44:20
Check Details
阿法替尼延长肺腺癌患者的生存时间
2025-10-19 11:44:20
Check Details
奥希替尼获批治疗EGFR突变非小细胞肺癌
2025-10-19 11:44:20
Check Details
1
2
...
3024
3025
3026
3027
3028
3029
3030
...
4161
4162
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Binimetinib plus Encorafenib for BRAF‑Mutant Melanoma
2
Adagrasib (Krazati) for KRAS G12C: NSCLC Dosing, Titration, and CRC Regulatory Update
3
Ceritinib for ALK-Positive NSCLC: Indication, Dosing, and Safety Management
4
Enzalutamide for Prostate Cancer: Managing Fatigue, Dizziness, Hypertension, and Serious Neurocardiovascular Risks
5
Tamoxifen Long-Term Safety: Vigilance for Thrombosis and Endometrial Risks
6
Acoramidis for ATTR-CM: Disease Progression Is Not Equivalent to Drug Resistance
7
Lorlatinib Contraindications and Safety Warnings: Six Key Risks to Monitor
8
Dacomitinib for EGFR-Mutant NSCLC: Dosing, Switching, and Safety Profile
9
Abemaciclib for HR+ HER2- Breast Cancer: Mechanism, Combination Therapy, and Switching Considerations
10
Cemiplimab Mechanism of Action: How PD-1 Inhibition Restores Antitumor Immunity
11
Tivozanib Dosing Guide for Renal Cell Carcinoma: 21-Day On/7-Day Off Cycle and Adjustments
12
Selpercatinib: Dosing and Administration Essentials of an Oral RET Inhibitor